Serious arterial thromboembolic events (sATE) in patients (PTS) with metastatic colorectal cancer (MCRC) treated with bevacizumab (BV): Results from the BRiTE registry

被引：0

作者：

Sugrue, M.

Yi, J.

Purdie, D.

Dong, W.

Grothey, A.

Kozoff, M.

机构：

[1] Genentech Inc, San Francisco, CA 94080 USA

[2] Mayo Clin, Rochester, MN USA

[3] Ingalls Hosp, Harvey, IL USA

[4] Univ Chicago, Harvey, IL USA

来源：

ANNALS OF ONCOLOGY | 2007年 / 18卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：VII30 / VII30

页数：1

共 50 条

[41] Safety of capecitabine plus bevacizumab in heavily treated patients with metastatic colorectal cancer (MCRC)
Adamo, Vincenzo
Festa, Vincenzo
Restuccia, Eleonora
Chiofalo, Giuseppe
Maisano, Carmelo
Picciotto, Maria
Alafaci, Elisabetta
Tortora, Giampaolo
ANNALS OF ONCOLOGY, 2007, 18 : 16 - 17
[42] Phase Ib study of drozitumab combined with cetuximab (CET) plus irinotecan (IRI) or with FOLFIRI with or without bevacizumab (BV) in previously treated patients (pts) with metastatic colorectal cancer (mCRC).
Baron, A. D.
O'Bryant, C. L.
Choi, Y.
Royer-Joo, S.
Portera, C. C.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
[43] FOLFOXIRI plus bevacizumab (BEV) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): Preliminary safety results from the OPAL study
Stein, Alexander
Atanackovic, Djordje
Hildebrandt, Bert
Stuebs, Patrick
Steffens, Claus-Christoph
Brugger, Wolfram
Hapke, Gunnar
Illerhaus, Gerald
Bluemner, Ernst
Bokemeyer, Carsten
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
[44] Survival Outcomes With Use of Bevacizumab Beyond Progression (BBP) in Metastatic Colorectal Cancer (MCRC) Patients (Pts)
Cartwright, T.
Yu, E.
Yim, Y.
Hartnett, H.
Chung, H.
Halm, M.
Forsyth, M.
EUROPEAN JOURNAL OF CANCER, 2011, 47 : S437 - S437
[45] Efficacy and safety of bevacizumab (BEV) plus chemotherapy in Chinese patients (pts) with metastatic colorectal cancer (mCRC): Results from the ARTIST study.
Guan, Z.
Xu, J.
Luo, R.
Feng, F.
Wang, L.
Shen, L.
Yu, S.
Ba, Y.
Liang, J.
Wang, D.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[46] Impact of first-line bevacizumab (BV) on the clinical outcomes of patients with metastatic colorectal cancer (mCRC) treated with second-line FOLFIRI plus BV
Muro, Kei
Yamanaka, Takeharu
Suenaga, Mitsukuni
Nishina, Tomohiro
Yasul, Hisateru
Ura, Takashi
Denda, Tadamichi
Ikeda, Junichi
Esakl, Taito
Nishisaki, Hogara
Takano, Yoshinao
Kondo, Ken
Takeda, Koji
Takahashi, Yasuo
Endo, Kazuya
Sugiyama, Yasuyuki
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[47] SAFETY OUTCOMES ASSOCIATED WITH LONG-TERM, CONTINUOUS EXPOSURE TO BEVACIZUMAB (BV) AND CHEMOTHERAPY (CT) IN PATIENTS (PTS) WITH MCRC: RESULTS FROM THE BRITE OBSERVATIONAL COHORT STUDY
Kozloff, M.
Berlin, J.
Flynn, J.
Grothey, A.
Kabbinavar, F.
Sargent, D.
Dong, W.
Purdie, D.
Sugrue, M.
ANNALS OF ONCOLOGY, 2008, 19 : 132 - 132
[48] Benefit from bevacizumab (BV) is independent of pretreatment plasma vascular endothelial growth factor-A (pl-VEGF) in patients (pts) with metastatic colorectal cancer (mCRC).
Holden, SN
Ryan, E
Kearns, A
Holmgren, E
Hurwitz, H
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 259S - 259S
[49] SYSTEMIC LV5FU2 WITH HEPATIC ARTERIAL INFUSION (HAI) OXALIPLATIN ± BEVACIZUMAB IN PATIENTS (PTS) WITH METASTATIC, HEAVILY PRE - TREATED COLORECTAL CANCER (mCRC)
Rahal, Arslane
Malka, David
Boige, Valerie
Elias, Dominique
Goere, Diane
De Baere, Thierry
Deschamps, Frederic
Rahal, Chahinez
Ducreux, Michel
ANNALS OF ONCOLOGY, 2011, 22 : v97 - v97
[50] Molecular characterization of metastatic colorectal cancer (mCRC) in patients (pts) treated with cetuximab and pembrolizumab.
Fountzilas, Christos
Rosario, Spencer
Withers, Henry G.
Mukherjee, Sarbajit
Bajor, David L.
Saltzman, Joel N.
Wang, Chong
Attwood, Kristopher
Knudsen, Erik S.
Witkiewicz, Agnieszka K.
Iyer, Renuka V.
Boland, Patrick M.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 178 - 178

← 1 2 3 4 5 →